The global effort to eliminate HCV infection requires new approaches to accessing and testing the affected population in a setting with as low of a threshold as possible. The focus should be on socially marginalized people who inject drugs (PWIDs) and who are not willing or able to visit standard medical services. With this vision, we established an outreach service-a testing point in an ambulance in the park in front of the Main Railway Station of the capital city of Prague-to provide bloodborne disease testing and treatment. The service was available every week on Wednesday afternoon. Over the initial two years of our experience, 168 unique people were tested. Of them, 82 (49%) were diagnosed with chronic HCV infection and were eligible for treatment with antivirals. Of these, 24 (29%) initiated antiviral treatment over the study period, and 17 (71%) of these individuals achieved a documented sustained virological response. Offering medical services in PWIDs' neighborhoods helps overcome barriers and increase the chances that they will become patients and begin HCV treatment. The described outcomes appear promising for reaching the vision of linkage to the care of such a hard-to-reach population and can serve as a feasible model of care for further expansion.

4th Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Kateřinská 32 128 00 Prague 2 Czech Republic

Remedis s r o Vladimírova 10 140 00 Prague 4 Czech Republic

Zobrazit více v PubMed

Larney S., Peacock A., Mathers B.M., Hickman M., Degenhardt L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39–49. doi: 10.1016/j.drugalcdep.2016.11.029. PubMed DOI

Levitt A., Mermin J., Jones C.M., See A., Butler J.C. Infectious Diseases and Injection Drug Use: Public Health Burden and Response. J. Infect. Dis. 2020;222((Suppl. 5)):S213–S217. doi: 10.1093/infdis/jiaa432. PubMed DOI

Degenhardt L., Charlson F., Stanaway J., Larney S., Alexander L.T., Hickman M., Cowie B., Hall W.D., Strang J., Whiteford H., et al. Estimating the burden of disease attributable to injecting drug use as a risk factorfor HIV, hepatitis C, and hepatitis B: Findings from the Global Burden of Disease Study 2013. Lancet Infect. Dis. 2016;16:1385–1398. doi: 10.1016/S1473-3099(16)30325-5. PubMed DOI

World Health Organization . Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection. World Health Organization; Geneva, Switzerland: 2016.

Wiessing L., Ferri M., Grady B., Kantzanou M., Sperle I., Cullen K.J., EMCDDA DRID group. Hatzakis A., Prins M., Vickerman P., et al. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS ONE. 2014;9:e103345. doi: 10.1371/journal.pone.0103345. PubMed DOI PMC

Grebely J., Larney S., Peacock A., College S., Leung J., Hickman M., Vickerman P., Blach S., Cunningham E.B., Dumchev K., et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114:150–166. doi: 10.1111/add.14393. PubMed DOI PMC

World Health Organization . Global Hepatitis Report 2017. World Health Organization; Geneva, Switzerland: 2017.

World Health Organization . Global Health Sector Strategy on Viral Hepatitis 2016–2021: Towards Ending Viral Hepatitis. World Health Organization; Geneva, Switzerland: 2016.

World Health Organization . Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief. World Health Organization; Geneva, Switzerland: 2016.

Degenhardt L., Peacock A., Colledge S., Leung J., Grebely J., Vickerman P., Stone J., Cunningham E.B., Trickey A., Dumchev K., et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Glob. Health. 2017;5:e1192–e1207. doi: 10.1016/S2214-109X(17)30375-3. PubMed DOI PMC

Martin N.K., Vickerman P., Dore G.J., Hickman M. The he-patitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM) Curr. Opin. HIV AIDS. 2015;10:374–380. doi: 10.1097/COH.0000000000000179. PubMed DOI PMC

Heffernan A., Cooke G.S., Nayagam S., Thursz M., Hallett T.B. Scaling up prevention and treatment towards the elimination of hepatitis C: A global mathematical model. Lancet. 2019;393:1319–1329. doi: 10.1016/S0140-6736(18)32277-3. PubMed DOI PMC

Hickman M., De Angelis D., Vickerman P., Hutchinson S., Martin N. Hepatitis C virus treatment as prevention in people who inject drugs. Curr. Opin. Infect. Dis. 2015;28:576–582. doi: 10.1097/QCO.0000000000000216. PubMed DOI PMC

Martin N.K., Vickerman P., Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J. Theor. Biol. 2011;274:58–66. doi: 10.1016/j.jtbi.2010.12.041. PubMed DOI

Harris M., Albers E., Swan T. The promise of treatment as pre-vention for hepatitis C: Meeting the needs of people who inject drugs? Int. J. Drug Policy. 2015;26:963–969. doi: 10.1016/j.drugpo.2015.05.005. PubMed DOI

Krekulova L. Epidemie Virové Hepatitidy C v Rizikových Populacích: Diagnostika, Léčba a Eliminační Strategie. Stanislav Juhaňák—Triton; Prague, Czech Republic: 2021.

Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., et al. Randomised trial of in-terferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepa-titis C virus. Lancet. 1998;352:1426–1432. doi: 10.1016/S0140-6736(98)07124-4. PubMed DOI

McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling H.M., Cort S., Albrecht J.K. Interferon Alfa2b Alone or in Combination with Ribavirin as Initial Treatment or Chronic Hepatitis C. N. Engl. J. Med. 1998;339:1485–1492. doi: 10.1056/NEJM199811193392101. PubMed DOI

Ghany M.G., Morgan T.R., AASLD-IDSA Hepatitis C Guidance Panel Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686–721. doi: 10.1002/hep.31060. PubMed DOI PMC

EASL EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2022;69:P461–P511. PubMed

Pawlotsky J.M., Negro F., Aaghemo A., Berenguer M., Dalgard O., Dusheiko G., Marra F., Puotti M., Wedemeyer H. EASL recommenda-tions on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020;73:1170–1218. doi: 10.1016/j.jhep.2020.08.018. PubMed DOI

Urbánek P., Husa P., Šperl J., Fraňková S., Plíšek S., Rožnovský L., Kümpel P. Standard diagnostic and therapeutic approaches to chronic hepatitis C virus infection. Gastroent. Hepatol. 2015;69:455–471. doi: 10.14735/amgh2015455. DOI

Razavi H., Robbins S., Zeuzem V., Negro F., Buti M., Duberg A.S., Thoraval F.R., Craxi A., Manns M., Marinho R.T., et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: A modelling study. Lancet Gastroenterol. Hepatol. 2017;2:325–336. doi: 10.1016/S2468-1253(17)30045-6. PubMed DOI

Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales Jr F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., et al. Peginterferon Alfa2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N. Engl. J. Med. 2002;347:975–982. doi: 10.1056/NEJMoa020047. PubMed DOI

Hadziyannis S.J., Sette Jr H., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer Jr H., Bernstein D., Rizzetto M., et al. Peginter-feron-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C. Ann. Intern. Med. 2004;140:975–982. doi: 10.7326/0003-4819-140-5-200403020-00010. PubMed DOI

U.S. Food and Drug Administration Neurological Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting [Docket No. FDA–2011–N–0002]; Proceedings of the Antiviral Drugs Advisory Committee Meeting; Silver Spring, MD, USA. 27–28 April 2011.

Flisiak R., Jaroszewicz J., Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin. Emerg. Drugs. 2013;18:461–475. doi: 10.1517/14728214.2013.847089. PubMed DOI

Asselah T., Marcellin P., Schinazi R.F. Treatment of hepati-tis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int. 2018;38:7–13. doi: 10.1111/liv.13673. PubMed DOI PMC

World Health Organization (WHO) Hepatitis C: Key Facts. 2019. [(accessed on 9 July 2019)]. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.

Edland-Gryt M., Skatvedt A.H. Thresholds in a low-thresh-old setting: An empirical study of barriers in a centre for people with drug problems and mental health disorders. Int. J. Drug Policy. 2013;24:257–264. doi: 10.1016/j.drugpo.2012.08.002. PubMed DOI

Mravcik V., Strada L., Stolfa J., Bencko V., Groshkova T., Reimer J., Schulte B. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: A literature review. Patient Prefer. Adherence. 2013;7:1067–1075. doi: 10.2147/PPA.S49113. PubMed DOI PMC

Larney S., Peacock A., Leung J., College S., Hickman M., Vickerman P., Grebely J., Dumchev K.J., Griffiths P., Hinnes L., et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C (17)30373-X. Lancet Glob. Health. 2017;5:e1208–e1220. doi: 10.1016/S2214-109X(17)30373-X. PubMed DOI PMC

Hagan H., Pouget E.R., Des Jarlais D.C. A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs. J. Infect. Dis. 2011;204:74–83. doi: 10.1093/infdis/jir196. PubMed DOI PMC

Harris M., Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduct. J. 2013;10:7. doi: 10.1186/1477-7517-10-7. PubMed DOI PMC

Marshall A.D., Grebely J., Dore G.J., Treloar C. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—The practitioner experience. Drug Alcohol Depend. 2020;206:107705. doi: 10.1016/j.drugalcdep.2019.107705. PubMed DOI

Madden A., Hopwood M., Neale J., Treloar C. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS ONE. 2018;13:e0207226. doi: 10.1371/journal.pone.0207226. PubMed DOI PMC

Larney S., Grebely J., Hickman M., Angelis D.D., Dore G.J., Degenhardt L. Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. Int. J. Drug Policy. 2015;26:950–957. doi: 10.1016/j.drugpo.2015.07.010. PubMed DOI

Gibbs D., Price O., Grebely J., Larney S., Sutherland R., Read P., Butler K., Degenhardt L., Peacock A. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. Drug Alcohol Depend. 2021;228:109050. doi: 10.1016/j.drugalcdep.2021.109050. PubMed DOI

Bajis S., Grebely J., Hajarizadeh B., Applegate T., Marshall A.D., Harrod M.E., Byrne J., Bath N., Read P., Edwards M., et al. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre-and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. J. Viral Hepat. 2020;27:281–293. doi: 10.1111/jvh.13233. PubMed DOI

Butler K., Larney S., Day C.A., Burns L. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system. Drug Alcohol Rev. 2019;38:264–269. doi: 10.1111/dar.12883. PubMed DOI

Harney B.L., Whitton B., Lim C., Paige E., Mcdonald B., Nolan S., Pemberton D., Hellard M.E., Doyle J.S. Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia. Int. J. Drug Policy. 2019;72:195–198. doi: 10.1016/j.drugpo.2019.02.012. PubMed DOI

Beiser M.E., Smith K., Ingemi M., Mulligan E., Baggett T.P. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int. J. Drug Policy. 2019;72:129–137. doi: 10.1016/j.drugpo.2019.03.017. PubMed DOI

Valerio H., Alavi M., Conway A., Silk D., Treloar C., Martinello M., Milat A., Dunlop A., Murray C., Henderson C., et al. Declining Prevalence of Current HCV Infection and Increased Treatment Uptake Among People Who Inject Drugs: The ETHOS Engage Study. Int. J. Drug Policy. 2022;105:103706. doi: 10.1016/j.drugpo.2022.103706. PubMed DOI

Beiser M., Leon C., Gaeta J.M. Needs assessment of HCV-infected individuals experiencing homelessness and implications. J. Health Care Poor Underserved. 2017;28:596–606. doi: 10.1353/hpu.2017.0042. PubMed DOI

Read P., Lothian R., Chronister K., Gilliver R., Kearley J., Dore G.J., van Beek I. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int. J. Drug Policy. 2017;47:209–215. doi: 10.1016/j.drugpo.2017.05.032. PubMed DOI

Broad J., Mason K., Guyton M., Lettner B., Matelski J., Powis J. Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada. Int. J. Drug Policy. 2020;80:102755. doi: 10.1016/j.drugpo.2020.102755. PubMed DOI

Surey J., Menezes D., Francis M., Gibbons J., Sultan B., Miah A., Abubakar I., Story A. From peer-based to peer-led: Redefining the role of peers across the hepatitis C care pathway: HepCare Europe. J. Antimicrob. Chemother. 2019;74((Suppl. 5)):v17–v23. doi: 10.1093/jac/dkz452. PubMed DOI PMC

Socias M., Karamouzian M., Parent S., Barletta J., Bird K., Ti L. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review. Int. J. Drug Policy. 2019;72:146–159. doi: 10.1016/j.drugpo.2019.05.023. PubMed DOI

Treloar C., Rance J., Dore G.J., Grebely J. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: Insights from the ETHOS study. J. Viral Hepat. 2014;21:560–567. doi: 10.1111/jvh.12183. PubMed DOI

Oru E., Trickey A., Shirali R., Kanters S., Easterbrook P. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: A global systematic review and meta-analysis. Lancet Glob. Health. 2021;9:e431–e445. doi: 10.1016/S2214-109X(20)30505-2. PubMed DOI PMC

Stvilia K., Vephkvadze N., Gamkrelidze A., Khonelidze I., Getia V., Tsereteli M., Gvinjilia L., Kuchuloria T. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia. Public Health. 2021;195:42–50. doi: 10.1016/j.puhe.2021.03.017. PubMed DOI

Zabransky T., Mravcik V., Korcisova B., Rehak V. Hepatitis C Virus Infection among Injecting Drug Users in the Czech Republic—Prevalence and Associated Factors. Eur. Addict. Res. 2006;12:151–160. doi: 10.1159/000092117. PubMed DOI

Mravcik V., Chomynova P., Grohmanova K., Janikova B., Černíková T., Rous Z., Leštinová T., Nechanská B., Cibulka J., Fidesova H., et al. Výroční Zpráva o Stavu ve Věcech Drog v České Republice v Roce 2018 (Annual Report on Drug Situation 2018—Czech Republic) Úřad Vlády ČR; Prague, Czech Republic: 2019.

Razavi H., Waked I., Sarrazin C., Myers R.P., Idilman R., Calinas F., Vogel W., Mendes Correa M.C., Hézode C., Lázaro P., et al. The present and future di-sease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J. Viral Hepat. 2014;21((Suppl. 1)):34–59. doi: 10.1111/jvh.12248. PubMed DOI

Grebely J., Raffa J.D., Lai C., Krajden M., Kerr T., Fischer B., Tyndall M.W. Low uptake of treatment for hepatitis C virus infec-tion in a large community-based study of inner city residents. J. Viral Hepat. 2009;16:352–358. doi: 10.1111/j.1365-2893.2009.01080.x. PubMed DOI

Mehta S.H., Genberg B.L., Astemborski J., Kavasery R., Kirk G.D., Vlahov D., Strathdee S.A., Thomas D.L. Limited Uptake of Hepatitis C Treatment Among Injection Drug Users. J. Commun. Health. 2008;33:126–133. doi: 10.1007/s10900-007-9083-3. PubMed DOI PMC

Grebely J., Bruggmann P., Treloar C., Byrne J., Rhodes T., Dore G.J. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. Int. J. Drug Policy. 2015;26:893–898. doi: 10.1016/j.drugpo.2015.07.007. PubMed DOI

Yousafzai M.T., Bajis S., Alavi M., Grebely J., Dore G.J., Hajarizadeh B. Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis. J. Viral Hepat. 2021;28:1340–1354. doi: 10.1111/jvh.13574. PubMed DOI

Stvilia K., Khonelidze I., Gamkrelidze A., Asatiaan A., Ruadze E., Gogia M., Kutateladze K., Jikhia G. HCV care cascade of PWIDs reached within the Global Fund Needle and Syringe Program (NSP) in Georgia. J. Hepatol. 2019;70:e343. doi: 10.1016/S0618-8278(19)30671-1. DOI

Iversen J., Dore G.J., Catlett B., Cunningham P., Grebely J., Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J. Hepatol. 2019;70:33–39. doi: 10.1016/j.jhep.2018.09.030. PubMed DOI

Iversen J., Dore G.J., Starr M., Catlett B., Cunningham P., Geddes L., Maher L. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. Int. J. Drug Policy. 2020;83:102837. doi: 10.1016/j.drugpo.2020.102837. PubMed DOI

Gamkrelidze I., Pawlotsky J.M., Lazarus J.V., Feld J.J., Zeuzem S., Bao Y., Pires dos Santos A.G., Gonzalez Y.S., Razavi H. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. Liver Int. 2021;41:456–463. doi: 10.1111/liv.14779. PubMed DOI